Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Precigen Inc (Precigen) is a clinical-stage biopharmaceutical company that carries out the discovery and development of gene and cell therapies. The company's activities focus on advancing precision technology in the areas of immuno-oncology, autoimmune disorders, and infectious diseases. Its offerings include AdenoVerse pipeline such as PRGN-2012, PRGN-2009+pembrolizumab; and UltraCAR-T pipeline, such as PRGN-3006, PRGN-3005, and PRGN-3007. Precigen's products are utilized by healthcare providers and researchers to develop treatments for complex diseases, particularly in the medical and biotechnology industries. The company operates in the US, and Belgium. Precigen is headquartered in Germantown, Maryland, the US.
Headquarters
United States of America
Address
20358 Seneca Meadows Parkway, Germantown, Maryland, 20876
Website
precigen.com
Telephone
1 301 5569900
No of Employees
160
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
PGEN (NASD)
Revenue (2024)
$9.7M
146.7%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-98.6%
(2024 vs 2023)
Market Cap*
$1.9B
Net Profit Margin (2024)
XYZ
19.5%
(2024 vs 2023)
* As of and is in US$
Precigen Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | UltraCAR-T |
| AdenoVerse Pipeline: | AdenoVerse |
| PRGN-2012: Recurrent Respiratory Papillomatosis | ActoBiotics |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In October, the company selected Cencora for logistics and distribution support for the US commercial launch of Precigen’s novel immunotherapy. |
| 2025 | Regulatory Approval | In February, the company received acceptance from the US Food and Drug Administration for PRGN-2012, an investigational AdenoVerse gene therapy for the treatment of adults with recurrent respiratory papillomatosis (RRP). |
| 2024 | Regulatory Approval | In December, the company completed the submission for a biologics license application to the US Food and Drug Administration for PRGN-2012 (INN: zopapogene imadenovec†) to treat adult patients with recurrent respiratory papillomatosis. |
Competitor Comparison
| Key Parameters | Precigen Inc | Merck & Co Inc | AbbVie Inc | AstraZeneca Plc | Bristol-Myers Squibb Co |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United Kingdom | United States of America |
| City | Germantown | Rahway | North Chicago | Cambridge | Princeton |
| State/Province | Maryland | New Jersey | Illinois | Cambridgeshire | New Jersey |
| No. of Employees | 160 | 75,000 | 57,000 | 96,100 | 32,500 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Randal J. Kirk | Chairman | Executive Board | 2026 | 72 |
| Helen Sabzevari, PhD | Chief Executive Officer; President; Director | Executive Board | 2020 | 64 |
| Harry Thomasian | Chief Financial Officer | Senior Management | 2021 | 64 |
| Rutul R. Shah | Chief Operating Officer | Senior Management | 2022 | 45 |
| Donald P. Lehr | Chief Legal Officer | Senior Management | 2011 | 51 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer